Related by context. All words. (Click for frequent words.) 73 Aliskiren 73 Enzastaurin 73 receptor tyrosine kinase inhibitor 73 Blinatumomab 73 Safinamide 73 Oral Fingolimod 73 oral prodrug 73 Deforolimus 72 Romiplostim 72 Dasatinib 72 Elagolix 72 Kinase Inhibitor 72 Bosutinib 72 Hsp# Inhibitor 72 Roflumilast 71 investigational humanized monoclonal antibody 71 Aflibercept 71 Golimumab 71 Sapacitabine 71 Randomized Double blind 71 Antitumor Activity 71 fosbretabulin 71 Epratuzumab 71 Preclinical Models 71 Zarnestra 71 generation purine nucleoside 71 Achieves Primary Endpoint 71 Archexin 71 Vicriviroc 71 HDAC Inhibitor 71 Aurora Kinase 71 Phase 2a Clinical Trial 71 Investigational Treatment 71 Tyrosine Kinase Inhibitor 71 sodium glucose cotransporter 71 multi kinase inhibitor 71 Tezampanel 71 Nilotinib 71 Lubiprostone 70 Temsirolimus 70 Clinical Trial Results 70 Tasimelteon 70 Daclizumab 70 Pirfenidone 70 sorafenib Nexavar 70 Pralatrexate 70 Phase 2b Clinical Trial 70 Vandetanib 70 Eculizumab 70 Silodosin 70 Study Evaluating 70 Ambrisentan 70 Sipuleucel T 70 Ocrelizumab 70 selective modulator 70 Immunotherapeutic 70 Liposomal 70 Talabostat 70 Meets Primary Endpoint 70 Investigational Compound 70 mTOR mammalian target 70 dual endothelin receptor antagonist 70 Tumor Necrosis Factor 70 Everolimus 70 FOLOTYN ® 70 Boceprevir 70 Febuxostat 70 Pulmonary Arterial Hypertension 70 Dapagliflozin 70 Muraglitazar 70 Drug Candidate 69 non nucleoside inhibitor 69 Receptor Antagonist 69 Pharmacokinetic Study 69 PKC# 69 Diabetic Neuropathy 69 Phase IIa Clinical Trial 69 Vidaza azacitidine 69 Squalamine 69 Receptor Antagonists 69 PEGylated Fab fragment 69 Omacetaxine 69 Phase 2b Trial 69 Randomized Phase 69 mTOR inhibitor 69 Initiates Clinical 69 Initiate Phase 69 Novel Oral 69 IL# PE#QQR 69 TNF Tumor Necrosis Factor 69 Panzem R 69 Pazopanib 69 Tolvaptan 69 polycythemia vera essential thrombocythemia 69 beta 1a 69 Phase 2b Study 69 Iloperidone 69 Maribavir 69 Inhalation Solution 69 LymphoStat B belimumab 69 Teriflunomide 69 Fingolimod 69 Intravitreal 69 highly selective inhibitor 69 liposomal formulation 69 Hormone Refractory Prostate Cancer 69 Novel Mechanism 69 Pafuramidine 69 Anti Tumor 69 PEGylated anti 69 Irinotecan 69 Preclinical Study 69 Demonstrates Efficacy 69 Romidepsin 69 Pharmacokinetics PK 69 mertansine 69 Adjuvant Treatment 69 denileukin diftitox 69 Trandolapril 69 Anidulafungin 69 targeted antifolate 69 PDE4 inhibitor 69 CEQ# 69 Bucindolol 69 RhuDex 69 Successfully Completes Phase 69 riociguat 69 Lenalidomide 69 Personalized Immunotherapy 69 BZL# 68 Potent Inhibitor 68 thalidomide Thalomid 68 Tiotropium 68 LAB CGRP 68 Degarelix 68 Catena ® 68 Relapsed Refractory 68 Naive Patients 68 nucleoside analog 68 Enzyme Replacement Therapy 68 myelodysplastic myeloproliferative diseases 68 Phase 1b clinical trials 68 Factor Receptor 68 Voreloxin 68 Ozarelix 68 antibody MAb 68 sitaxsentan 68 Pivotal Phase III 68 histone deacetylase HDAC inhibitor 68 Darusentan 68 Methylnaltrexone 68 CYT# QbG# 68 Abatacept 68 Tanespimycin 68 MAGE A3 ASCI 68 essential thrombocythemia ET 68 Acute Ischemic Stroke 68 novel histone deacetylase 68 Receptor Agonist 68 adalimumab Humira 68 Begins Dosing 68 Glufosfamide 68 Traficet EN 68 Adalimumab 68 gefitinib Iressa 68 Pertuzumab 68 TLK# 68 Myelofibrosis 68 Phase IIb Trial 68 anti angiogenic agent 68 Zorbtive TM 68 Tyrima 68 vidofludimus 68 Cinacalcet 68 RNAi Therapeutic 68 Ceflatonin 68 Patients Treated With 68 Long Term Efficacy 68 Prolongs Survival 68 Carfilzomib 68 Vernakalant 68 Phase III Clinical Trial 68 Complicated Skin 68 Epidermal Growth Factor Receptor 68 Phase Ib clinical 68 R lenalidomide 68 Candesartan 68 Protease Inhibitor 68 INCB# [003] 68 Omalizumab 68 humanized monoclonal 68 selective agonist 68 efaproxiral 68 angiogenesis inhibitor 68 metastatic malignant 68 BAL# [002] 68 dasatinib Sprycel 68 Angiogenic 68 small molecule tyrosine 68 Tolerability 68 Parathyroid Hormone 68 Oral Spray 68 Presents Preclinical 68 Dalbavancin 68 YONDELIS 68 Tesetaxel 68 Lymphocytic 68 Completes Patient Enrollment 68 Bosentan 68 Phase 2a Study 68 Pemetrexed 68 Dose Escalation 68 Angiotensin Converting Enzyme 68 Malignant Glioma 68 Fidaxomicin 67 sunitinib Sutent 67 Combination REOLYSIN R 67 sorafenib tablets 67 refractory chronic lymphocytic 67 Gefitinib 67 GW# [003] 67 mGluR5 NAM 67 Estrogen Receptor 67 Vidofludimus 67 Previously Treated 67 Receives Orphan Drug Designation 67 chronic eosinophilic leukemia 67 Janus kinase 67 Factor VIIa 67 Antitumor 67 BRIM2 67 EVIZON TM 67 Fondaparinux 67 leukotriene receptor antagonist 67 ORENCIA ® 67 Pivotal Phase 67 Etanercept 67 Cyclooxygenase 2 67 Erlotinib 67 hypereosinophilic syndrome 67 selective kinase inhibitor 67 Granulocyte Colony Stimulating Factor 67 Elacytarabine 67 Antiviral Therapy 67 Olaparib 67 Phase III Trial 67 Neoadjuvant 67 ACTEMRA TM 67 Ofatumumab 67 Laquinimod 67 selective antagonist 67 Eltrombopag 67 Kinase Inhibitors 67 proteasome inhibitor 67 CYP#A# CYP#D# 67 Bortezomib 67 ZACTIMA 67 efalizumab 67 Well Tolerated 67 cathepsin K inhibitor 67 erlotinib Tarceva ® 67 BAY #-# 67 selective phosphodiesterase 67 Atrasentan 67 Mipomersen 67 cetuximab Erbitux R 67 Shows Statistically Significant 67 Pivotal Study 67 Controlled Study 67 Pramlintide 67 VAPRISOL 67 Zybrestat 67 Hedgehog Pathway Inhibitor 67 mTOR kinase 67 Presents Preclinical Data 67 Cloretazine 67 Therapeutic Potential 67 HQK 67 Rigel R# 67 evaluating tivozanib 67 Xanafide 67 IMA# 67 Telbivudine 67 Pooled Analysis 67 CIMZIA TM certolizumab pegol 67 antibody MT# 67 diarrhea predominant irritable 67 benign prostatic hypertrophy BPH 67 Oral Formulation 67 erlotinib Tarceva 67 DDP# 67 Double Blind Placebo 67 Orally Active 67 SUTENT ® 67 Quinamed 67 Pivotal Trial 67 Ridaforolimus 67 Interferon Alfa 67 Interferon beta 67 sunitinib Sutent ® 67 peripherally acting 67 pan histone deacetylase 67 oral renin inhibitor 67 Lung Cancer Drug 67 ara C 67 Kuvan sapropterin dihydrochloride 67 Hepatocellular Carcinoma 67 MKC# MKC# PP 67 Initiates Phase III 67 vapreotide acetate 67 Lupus Nephritis 67 CTAP# Capsules 67 Recombinant Human 67 Ataluren 67 novel VDA molecule 67 Disease Progression 67 developing Bicifadine serotonin 67 somatostatin analog 67 Diabetic Nephropathy 67 Lacosamide 67 acetonide FA 67 teriflunomide 67 Demonstrates Significant 67 orally bioavailable 67 phase IIb clinical 67 investigational monoclonal antibody 67 induced macular edema 67 nucleotide analogue 67 MGd 67 Bevacizumab 67 tyrosine kinase inhibitor 67 ritonavir boosted 67 Sorafenib 67 Bronchiectasis 67 Ticagrelor 67 AFREZZA TM 67 Monotherapy 67 Transdermal Delivery 67 KRN# 67 Tasigna nilotinib 67 Azacitidine 67 Improves Outcomes 67 Tarceva TM 67 noninfectious uveitis 66 Montelukast 66 Efficacy Trial 66 Pegloticase 66 Mycophenolate Mofetil 66 R Saizen R 66 corticosteroid dexamethasone 66 Demonstrates Positive 66 lucinactant 66 Transdermal Patch 66 Treating Chronic 66 Aplidin 66 ZOLINZA 66 Initiates Clinical Trial 66 Phase 2a Trial 66 Bicalutamide 66 APTIVUS 66 Thiazolidinediones 66 Initiates Phase II 66 Glatiramer Acetate 66 Decitabine 66 Low Dose 66 ATL# [001] 66 Vitro Activity 66 phase IIb trial 66 FDA APPROVES 66 sunitinib malate 66 Anticancer Agent 66 VA# [002] 66 bortezomib Velcade 66 Polymerase Inhibitor 66 TNF Blockers 66 Seliciclib 66 humanized interleukin 6 66 abacavir Ziagen 66 vascular disrupting agent 66 Linaclotide 66 Fulvestrant 66 Cethrin R 66 brand ciclesonide HFA 66 Lamotrigine 66 Systemic Delivery 66 Prospective Randomized 66 JAK Inhibitor 66 Presents Positive 66 Gleevec resistant 66 cetuximab Erbitux 66 Chemokine Receptor 66 colesevelam HCl 66 Rivaroxaban 66 Novel Compound 66 intranasal formulation 66 chronic thromboembolic pulmonary 66 Interferon beta 1b 66 Tocilizumab 66 MAP# 66 Saforis 66 Atopic Dermatitis 66 Clofarabine 66 HuMax EGFr 66 anticancer compound 66 hormone LHRH antagonist 66 Initiates Enrollment 66 Peginterferon alfa 2b 66 LAF# 66 dasatinib Sprycel ® 66 AKT inhibitor 66 BCR ABL inhibitor 66 INSPIRE Trial Phase III 66 diabetic neuropathic pain 66 Cytotoxic T 66 pralatrexate injection folate analogue 66 Certolizumab pegol 66 RezularTM 66 aerosolized KL4 surfactant 66 STRIDE PD 66 Monoclonal antibody 66 Pathway Inhibitor 66 Guanilib 66 Hematological Malignancies 66 Ranolazine 66 Vaprisol 66 Akt activation 66 XYOTAX TM 66 Aclidinium 66 Fludara ® 66 Multiple Ascending Dose 66 aripiprazole Abilify 66 overactive bladder syndrome 66 endothelin receptor 66 Antiangiogenic 66 Doripenem 66 Replacement Therapy 66 Anti Tumor Activity 66 Imatinib mesylate 66 prucalopride 66 CYT# potent vascular disrupting 66 Almorexant 66 Liprotamase 66 ADP receptor antagonist 66 Allergic Rhinitis 66 Kamada AAT 66 chronic idiopathic thrombocytopenic purpura 66 Cethromycin 66 inhalation powder 66 Etravirine 66 Demonstrates Potent 66 Vorinostat 66 LymphoStat B TM 66 TBC# 66 Peginterferon 66 tipifarnib 66 midstage clinical 66 MKC# MT 66 Dose Ranging Study 66 Luteinizing Hormone Releasing Hormone 66 multikinase inhibitor 66 ergot derivatives 66 Vitaxin 66 IAP inhibitor 66 non peptidic protease 66 Inhaled nitric oxide 66 cell lymphoma CTCL 66 Ixempra 66 Investigational Drug 66 Diabetic Macular Edema DME 66 orally inhaled 66 Angiotensin II 66 topoisomerase II inhibitor 66 II Clinical Trial 66 JAK inhibitor 66 Annamycin 66 Granted Orphan Drug 66 5 HT2A serotonin 66 Rotigotine 66 docetaxel Taxotere ® 66 vinorelbine tartrate 66 INS# [001] 66 CDK inhibitor 66 OMNARIS HFA 66 visilizumab 66 Xeloda ® 66 Motavizumab 66 Ropinirole 66 small molecule thrombopoietin 66 Ciclesonide 66 Otelixizumab 66 MEK Inhibitor 66 alfa 2a 66 Zolinza 66 severe oral mucositis 66 Pagoclone 66 Plicera 66 SNT MC# 66 Onrigin 66 ALN HPN 66 UPLYSO 66 Combination Therapy 66 imatinib Gleevec ® 66 PNP inhibitor 66 registrational trial 66 Interferon Beta 66 Protein Kinase C 66 JAK2 Inhibitor 66 Saxagliptin 66 Advanced Melanoma 66 pertuzumab 66 oral dual endothelin 66 brivaracetam 66 Aztreonam 66 IgG1 monoclonal antibody 66 Patients Receiving 66 dopamine D2 66 targeting CD# 66 Oral Mucositis 66 Microplasmin 66 Preclinical Data 66 Faslodex 66 Fenretinide 66 Antiviral Activity 66 dyskinesia PD LID 66 selective androgen receptor modulator 66 norepinephrine reuptake inhibitor 66 Phase IIb Clinical Trial 66 Novel Small Molecule 66 Oritavancin 66 Clolar ® 66 AEG# 66 Bezielle 66 pregabalin Lyrica 66 Spiegelmer ® 66 Controlled Trial 66 Trial Evaluating 66 airway hydration 66 FDA Approvable Letter 65 Mitoxantrone 65 Rilonacept 65 Phase #b/#a clinical 65 Novel Inhibitor 65 Fluconazole 65 PF # [002] 65 albiglutide 65 Single Dose 65 Evoltra ® 65 Sprycel dasatinib 65 Protease Inhibitors 65 gastrointestinal stromal tumors GIST 65 LHRH receptor positive 65 opioid receptor antagonist 65 etanercept Enbrel 65 depsipeptide 65 Anthracycline 65 trial evaluating PRX# 65 Kinoid 65 Placebo Controlled Study 65 HuMax CD4 65 Initiates Clinical Trials 65 BRAF inhibitor 65 Receives Orphan Drug 65 chimeric monoclonal antibody 65 Heterozygous Familial Hypercholesterolemia 65 polymerase inhibitor 65 Shows Efficacy 65 HCV NS5B polymerase 65 Clinical Trial Evaluating 65 Nitazoxanide 65 mGluR2 positive 65 alvespimycin 65 MTP inhibitor 65 PI3 Kinase 65 virus HCV protease inhibitor 65 ENMD # 65 Darinaparsin 65 Natalizumab 65 hyperphenylalaninemia HPA due 65 Alvesco R 65 TRO# 65 Phase III Trials 65 pharmacokinetic PK 65 humanized anti 65 reslizumab 65 paclitaxel Taxol 65 panitumumab Vectibix 65 bosutinib 65 chemokine receptor 65 Eribulin 65 Allogeneic 65 Pivotal Clinical Trial 65 Double Blind Randomized 65 formerly LymphoStat B 65 generation antisense inhibitor 65 treat chronic sinusitis 65 Pimavanserin 65 SPIRIVA ® 65 See CLINICAL PHARMACOLOGY 65 Avanafil 65 Aviptadil 65 Valsartan 65 investigational immunotherapy 65 Drug Shows Promise 65 Zoloft sertraline 65 Dendritic Cells 65 Autologous Stem Cell Transplantation 65 Fludarabine 65 Combo Therapy 65 Bavituximab 65 Sym# 65 Adenosine 65 Hydroxyurea 65 antisense oligonucleotide 65 intravesical instillation 65 Rituxan rituximab 65 Melphalan 65 topically administered 65 Inflammatory Arthritis 65 Xelox 65 Unit Dose Budesonide 65 pan HDAC inhibitor 65 Present Preclinical Data 65 mapatumumab 65 FTY# fingolimod 65 SPRYCEL ® 65 Ustekinumab 65 Milnacipran 65 Antiarrhythmic 65 TACI Ig 65 Amrubicin 65 Afatinib 65 mGluR5 negative 65 mGluR2 65 Bronchodilator 65 idiopathic thrombocytopenic purpura ITP 65 ASTEROID 65 paclitaxel poliglumex 65 Late Breaker 65 methylnaltrexone bromide 65 investigational oral 65 vinca alkaloid 65 Phase III Clinical Trials 65 Clinical Outcome 65 orally inhaled migraine 65 Nexavar sorafenib 65 ALK inhibitor 65 somatostatin analogue 65 Randomized Study 65 orally administered inhibitor 65 Combination Treatment 65 Ranibizumab 65 IMiDs R 65 Clinical Efficacy 65 TO AVOID PREGNANCY WHILE 65 octreotide implant 65 verteporfin 65 Bafetinib 65 non metastatic osteosarcoma 65 serotonin norepinephrine reuptake inhibitor 65 DNA intercalator 65 VitiGam 65 Myelodysplastic Syndrome MDS 65 ThermoDox R 65 triciribine phosphate monohydrate 65 rituximab Rituxan 65 Adjunctive Therapy 65 Fluorouracil 65 Patient Enrollment 65 Placebo Controlled Trial 65 ixabepilone 65 Glatiramer acetate 65 Interferon beta 1a 65 Immunogenicity 65 Oral Insulin 65 EGFR tyrosine kinase inhibitor 65 guanfacine extended release 65 icatibant 65 Ecallantide 65 Phase 1a clinical 65 cMET 65 Neuvenge 65 miconazole Lauriad ® 65 First Patient Dosed 65 HDACi 65 pharmacokinetic PK study 65 Belimumab 65 Trodusquemine MSI 65 multicenter Phase II 65 Levetiracetam 65 Nexavar ® 65 TYGACIL 65 vemurafenib 65 Severe Sepsis 65 Moxifloxacin 65 Humanized Anti 65 Ziprasidone 65 protein tyrosine phosphatase 1B 65 brivanib 65 HuLuc# 65 vorinostat 65 INCB# [001] 65 Septic Shock 65 Metastatic Prostate Cancer 65 Dupuytren Contracture 65 lapatinib Tykerb 65 Cetrorelix 65 PEG SN# 65 prodrug stimulant 65 Curaxin CBLC# 65 Metastatic Melanoma 65 Cannabinor 65 relapsed MM 65 ALVESCO R 65 complement inhibitor eculizumab 65 mGluR2 NAM 65 Cytochrome P# 65 Randomized Double Blind Placebo 65 Atomoxetine 65 Glypromate 65 Demonstrates Statistically Significant 65 vaginal candidiasis 65 Tocosol Paclitaxel 65 randomized Phase IIb 65 Bevacizumab Avastin 65 CCX# 65 atazanavir sulfate 65 2A receptor agonist 65 TPI ASM8 65 RELOVAIR ™ 65 Initiated Phase 65 Announces Poster Presentations 65 BrachySil TM 65 Chronic Sinusitis 65 myeloid metaplasia 65 Renal Impairment 65 Subgroup Analysis 65 SomatoKine 65 Pioglitazone 65 HCV Genotype 65 Eniluracil 65 Hematological 65 ribavirin USP 65 trodusquemine 65 sphingosine 1 65 Novel Therapeutic 65 Carbamazepine 65 thetreatment 65 targeting miR 65 Fabry Disease 65 histone deacetylase inhibitor 65 enzastaurin 65 Linagliptin 65 oral salmon calcitonin 65 Vascugel 65 ATL/TV# 65 Analgesic 65 Ophena TM 65 AVASTIN 65 Noxafil 65 chronic granulomatous disease 65 alkylating agent 65 NDA Submission 65 baminercept 65 small molecule Hedgehog 65 Elesclomol 65 Toremifene 65 Inhalation Aerosol 65 Galantamine 65 angiotensin receptor blocker ARB 65 liposomal amphotericin B 65 Fodosine 65 JAK2 inhibitor 65 receptor inhibitor 65 6R BH4 65 Severe Asthma 64 GRN# 64 Adjunctive 64 Gout Drug 64 microtubule inhibitor 64 PSN# [002] 64 Phase 1b Clinical Trial 64 PRTX 64 Synta Announces 64 Hypercholesterolemia 64 PRT# 64 Radezolid 64 Letairis ambrisentan 64 rasagiline tablets 64 Sodium oxybate 64 rhIGF-I/rhIGFBP-3 64 Plecanatide 64 Systemic Sclerosis 64 seliciclib CYC# 64 mecamylamine 64 candesartan cilexetil 64 cyclin dependent kinase inhibitor 64 Thiovir 64 Lisofylline LSF 64 Aplidin R 64 cetrorelix pamoate 64 selective inhibition 64 Glucocorticoid 64 antisense inhibitor 64 targeted radiotherapeutic 64 docetaxel Taxotere R 64 Secondary Hyperparathyroidism 64 Panzem 64 Benign Prostatic Hyperplasia 64 R#/MEM # 64 Initiate Clinical Trial 64 Cutaneous T 64 SPL# Gel vaginal microbicide 64 oral JAK1 64 Chronic Myeloid Leukemia 64 topically applied SEPA 64 Reports Preclinical Data 64 Interferon Gamma 64 Randomized Phase II 64 AT1R 64 Abacavir 64 AA Amyloidosis 64 Is Well Tolerated 64 Rosuvastatin 64 Pharmacodynamics 64 M# rationally 64 octreotide acetate 64 Cetuximab Erbitux 64 Eprodisate 64 novel oral anticoagulant 64 metastatic colorectal 64 Antisense 64 Effectively Treats 64 Bremelanotide 64 forodesine 64 ALN TTR 64 denufosol 64 CYP#A# substrate 64 SNT-MC#/idebenone 64 Entecavir 64 Phase Ib Clinical Trial 64 immunomodulatory therapy 64 mu opioid receptor antagonist 64 torezolid 64 Investigational Agent 64 Tigecycline 64 Tesamorelin 64 Novel Antibiotic 64 Carbidopa 64 Immunomodulatory 64 Bazedoxifene 64 Anti VEGF 64 BCG refractory carcinoma 64 immunotherapeutic vaccine 64 Genasense ® oblimersen 64 EGFR TKI 64 PLX MS 64 LibiGel ® 64 CCX# B 64 Pegylated Interferon 64 Crizotinib 64 Itraconazole 64 Newly Diagnosed Multiple Myeloma 64 Intravail ® 64 phase Ib 64 posaconazole 64 Chronic Hepatitis C 64 midstage trials 64 inhaled formulation 64 huC# DM4 64 torezolid phosphate 64 ALVESCO ® 64 bevacizumab Avastin 64 SCH # 64 ELACYT 64 Relapsing Multiple Sclerosis 64 Bronchial Thermoplasty 64 ACE Inhibitors 64 Preclinical Evaluation 64 anti arrhythmic drug 64 AEGR 64 humanized therapeutic 64 Tipranavir 64 Zoraxel 64 BMS # 64 indinavir Crixivan 64 histamine dihydrochloride 64 2 methoxyestradiol 64 kidney urologic 64 biliary tract cancer 64 Phase III Pivotal 64 Mg Usa 64 aclidinium bromide 64 PDGF receptor 64 Lupus Drug 64 CA4P 64 Refractory Angina 64 Phase 2a clinical 64 Cystic Fibrosis Transmembrane conductance 64 Histone Deacetylase 64 edifoligide 64 Hematologic 64 tasimelteon 64 Syncria R 64 small molecule agonists 64 Incretin 64 Central Retinal Vein 64 Alequel 64 treat benign prostatic 64 Factor VEGF 64 RNAi Therapeutics 64 Zenvia ™ 64 salmeterol fluticasone 64 evaluating mipomersen 64 peptidic compound 64 inverse agonist 64 Raptiva ® 64 Cimzia TM 64 Shows Promising 64 Dyloject TM 64 Idiopathic Pulmonary Fibrosis 64 Myelodysplastic Syndromes 64 Shows Promise Against 64 Mirapexin 64 LHRH antagonists 64 Vaccine Adjuvant 64 Levoleucovorin 64 Mouse Model 64 Pharmacodynamic 64 Taxotere docetaxel 64 Gastrointestinal GI 64 Inhibitor 64 Glioma 64 monoclonal antibody MAb 64 Afinitor everolimus 64 protein kinase inhibitor 64 Fluticasone 64 Treated Patients 64 Therapeutic Antibody 64 interferon gamma 1b 64 IND Application 64 Velcade bortezomib 64 Bayer HealthCare Onyx Pharmaceuticals 64 Darapladib 64 Aurora kinase 64 PI3K/Akt pathway inhibitor 64 Atypical Hemolytic Uremic Syndrome 64 fenretinide 64 oral Janus kinase 64 Neoadjuvant Chemotherapy 64 transthyretin TTR mediated amyloidosis 64 GLYX 64 Alemtuzumab 64 CIMZIA R 64 Dacogen decitabine 64 Trabectedin 64 Azedra 64 RoACTEMRA 64 Deferiprone 64 Eszopiclone 64 Gleevec imatinib mesylate 64 HMG CoA reductase inhibitors 64 Medoxomil 64 canakinumab 64 orally dosed 64 Treatment Naïve 64 Ceflatonin R 64 metastatic neuroendocrine tumors 64 LAS# [002] 64 Demonstrates Potential 64 inhaled corticosteroid ICS 64 Aryplase 64 bosentan Tracleer 64 Protein Kinase 64 Desvenlafaxine Succinate 64 Tacrolimus 64 hour bronchodilation 64 Adjuvant Therapy 64 Tykerb lapatinib 64 Cell Lymphoma 64 Phase Ib II 64 NAGS deficiency 64 Non Alcoholic Steatohepatitis 64 Inhaled Corticosteroids 64 FOLFOX6 chemotherapy regimen 64 omalizumab Xolair 64 ® lenalidomide 64 Peripheral Arterial 64 ULORIC 64 Arranon 64 Vitrasert R 64 eltrombopag 64 Zileuton 64 Anti angiogenic 64 ruxolitinib 64 Advanced Renal Cell 64 luteinizing hormone releasing 64 acadesine 64 tiapamil 64 HGS ETR2